Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 16,430 matching trials from the live ClinicalTrials.gov search.
Conditions
Arginase I Deficiency, Hyperargininemia
Interventions
AEB1102
Drug
Lead sponsor
Immedica Pharma AB
Industry
Eligibility
2 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Stanford, California • Gainsville, Florida • New York, New York + 1 more
Not listed Not applicable Interventional

LFP Correlates of Movement Disorders

NCT02115802
Conditions
Parkinson's Disease
Interventions
Activa PC+S
Device
Lead sponsor
Colorado Neurological Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Englewood, Colorado
Conditions
Parkinson's Disease (Disorder)
Interventions
IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD
Drug · Other
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more
Conditions
Familial Amyotrophic Lateral Sclerosis
Interventions
Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
Drug
Lead sponsor
Edward Kasaraskis
Other
Eligibility
20 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Completed No phase listed Observational Accepts healthy volunteers

Predictors of Motor Progression in Parkinson's Disease

NCT02769039
Conditions
Parkinson's Disease
Interventions
No intervention. Observational studies of sleep, movement and brain imaging
Other
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Spinal Cord Injuries, Paraplegia and Tetraplegia
Interventions
transvertebral direct current stimulation (tvDCS)
Device
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Alzheimer's Disease
Interventions
Crenezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
66
States / cities
Phoenix, Arizona • Encino, California • Long Beach, California + 56 more
Conditions
Focal Epilepsy
Interventions
ENX-101
Drug
Lead sponsor
Engrail Therapeutics INC
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Downey, California + 31 more
Conditions
Brain Injury, Chronic
Interventions
Hyperbaric Oxygen, Minimal pressure air
Combination Product
Lead sponsor
Lindell Weaver
Other
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Conditions
Focal Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more
Conditions
Gender Identity, Gender Dysphoria in Adolescents and Adults, Headache, Transgender
Interventions
Testosterone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 20 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
75
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Conditions
Adult Glioblastoma, Depression, Recurrent Adult Brain Tumor
Interventions
vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Spinal Cord Injuries
Interventions
mindfulness meditation(MM), Health Education (active control)
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Houston, Texas
Completed Phase 3 Interventional Results available

Treatment for Endogenous Cushing's Syndrome

NCT01838551
Conditions
Endogenous Cushing's Syndrome
Interventions
Levoketoconazole
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Conditions
Movement Disorders, Energy Metabolism
Interventions
Doubly-Labeled Water
Other
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cortical Contributions to Motor Sequence Learning

NCT04138953
Conditions
Brain Injuries
Interventions
Transcranial Magnetic Stimulation (TMS), Sham TMS
Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Obsessive Compulsive Disorder, Body Dysmorphic Disorder, Tourette Syndrome, Trichotillomania, Panic Disorder, Social Phobia, Generalized Anxiety Disorder, Depression, Post-Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder, Eating Disorder, Specific Phobia, General Medical Condition
Interventions
Cognitive behavioral therapy (CBT)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Migraine Disorders, Aphasia
Interventions
Language treatment
Behavioral
Lead sponsor
Quality Living, Inc.
Other
Eligibility
19 Years to 65 Years
Enrollment
1 participant
Timeline
2018 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Essential Tremor
Interventions
SAGE-324, SAGE-324 Placebo
Drug
Lead sponsor
Sage Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
27
States / cities
Phoenix, Arizona • Rogers, Arkansas • Fresno, California + 23 more
Conditions
Central Nervous System Tumors
Interventions
BLZ-100
Drug
Lead sponsor
Blaze Bioscience Inc.
Industry
Eligibility
1 Month to 30 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Stroke
Interventions
Task-specific PCMS, Task-specific sham-PCMS, PCMS-rest
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Amblyopia
Interventions
Atropine, Plano Lens
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 6 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Fullerton, California • Dallas, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Error Augmentation for Neurorehabilitation

NCT01574495
Conditions
Stroke
Interventions
Error Augmentation
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois